Revive Announces IRB Approval of US Expanded Access Treatment Program for Bucillamine in COVID-19
Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19
© 2023 Frontier Merchant Capital Group. All Rights Reserved.